MINNEAPOLIS, March 10, 2025 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced that it has begun shipping the Leo™ System, powered by Simple Western™ Technology. Leo expands upon existing Simple Western platforms that offer automated protein size resolution and antibody-based protein detection by dramatically improving sample throughput and enhancing the reproducibility of protein quantitation. Leo offers the throughput and precision of standard ELISAs in a fully automated western blot assay, expanding applications in bioanalytical workflows from discovery through commercialization.
Leo enables the simultaneous processing of up to 100 samples in a single 3-hour run, offering 4x the throughput of the Jess™ Simple Western System and 5x faster turn-around-times than Sally Sue™ and Peggy Sue™ Simple Western Systems. Leo also provides the experimental size, precision and reproducibility necessary for robust analytical grade protein quantitation for use in submissions to regulatory agencies. Additionally, Leo features enhanced Compass for Simple Western Software, with advanced analysis capabilities and improvements to better support 21 CFR Part 11 Compliance.
“With Leo, scientists can achieve their development milestones faster and more efficiently, completing studies with fewer runs, operators and instruments,” commented Will Geist, President of Bio-Techne’s Protein Sciences Segment. “Leo will enable our customers to accelerate their cutting-edge science and bring next generation therapies to market faster.”
Early adopters have been thrilled with the power that Leo brings, with beta testers praising the instrument’s robust performance, data quality, and wide range of applications, including targeted protein degradation, clinical biomarker studies, gene therapy potency assays, quality control and release assays, recombinant protein expression and more.
Explore Leo’s capabilities at bio-techne.com/leo. Data on Leo’s performance will be presented at an upcoming webinar. Registration details can be found here.
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
SOURCE Bio-Techne Corporation
Vancouver, British Columbia--(Newsfile Corp. - April 9, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB:…
LA JOLLA, Calif., April 9, 2025 /PRNewswire/ -- Acurion, formerly known as io9, today announced…
New location marks the company's 45th clinic across New Jersey and Connecticut MENDHAM, N.J., April…
LOS ANGELES, April 9, 2025 /PRNewswire/ -- Agilisium – a leading Data Innovation & Agentic…
HENDERSON, Nev., April 9, 2025 /PRNewswire/ -- As healthcare data breaches surge to record levels, MEDVA,…
MINNEAPOLIS, April 9, 2025 /PRNewswire/ -- Health Care Compliance Association® (HCCA®) is proud to announce…